Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 43 versus VASCORAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 43 versus VASCORAY.
CONRAY 43 vs VASCORAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during imaging.
VASCORAY is a fixed combination of iodixanol and calcium sodium edetate. Iodixanol is a nonionic, dimeric, isotonic iodinated contrast medium that increases radiographic contrast by attenuating X-rays. Calcium sodium edetate chelates calcium, potentially reducing contrast-induced nephropathy risk.
Intravenous: 0.5-1.0 mL/kg (20-43 mg I/kg) for CT; intra-arterial: 5-15 mL for selective studies; maximum single dose 150 mL.
0.5-1.0 mL/kg intravenously as a single dose, not to exceed 5 mL/kg total.
None Documented
None Documented
2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life of 8-12 hours in patients with normal renal function; prolonged in renal impairment.
Renal: >90% via glomerular filtration; unchanged drug. Biliary: <1%. Fecal: negligible.
Primarily renal (90% unchanged), with 10% biliary/fecal.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent